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Erythema marginatum is a characteristic skin rash seen 
in patients with hereditary angioedema (HAE); however, 
it can be confused with urticaria, leading to delay in cor-
rect diagnosis. The aim of this study was to clarify how 
often erythema marginatum is misinterpreted as urtica-
ria, potentially leading physicians to refrain from testing 
for HAE. Few studies have been published on urticaria 
and prodromal symptoms in HAE, thus the incidence 
of these parameters were also investigated. A total of 87 
patients affiliated to the national HAE Centre were in-
cluded. Retrospective and prospective data on skin erup-
tions and prodromal symptoms were collected. Fifty-six 
percent of 87 patients had a positive history of erythema 
marginatum. Half of the patients had experienced ery-
thema marginatum being misinterpreted as urticaria. 
The most prevalent other prodromal symptoms were 
other skin symptoms, malaise, psychological changes, 
fatigue and gastrointestinal symptoms. HAE patients 
with erythema marginatum have a longer diagnostic de-
lay, presumably caused by misinterpretation of the rash 
as urticaria. Key words: hereditary angioedema; erythema 
marginatum; urticaria; prodromal symptoms.
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Hereditary angioedema (HAE) is an autosomal dominant 
inherited disease with bradykinin-mediated skin swel-
lings caused by a diminished level (type I) or function 
(type II) of complement C1 inhibitor (C1INH) due to mu-
tations of the SERPING1 gene (1). A third type of HAE 
with normal C1INH exists, which is often oestrogen-
sensitive and may be associated with mutations of the 
factor XII gene, F12 (2). HAE has been described in the 
medical literature since the 19th century, but only recently 
have effective treatment regimens been widely establish-
ed (1, 3). Angioedema is the main symptom of HAE, but 
a wide range of associated and prodromal symptoms 
have been systematically reported in recent studies (4–6). 
Among these, the most specific symptom is erythema 
marginatum (EM), which has attracted special attention 
in the literature since the original report by Dinckelacker 
in 1882 (7). EM is a reticular and serpiginous, usually 
non-pruritic, erythema (Fig. 1), mostly located on the up-
per trunk that might precede or accompany angioedema, 
although it can also occur independently (8). This type of 
rash has also been observed in association with rheumatic 
fever (9). EM is distinct from urticaria, which is pruritic, 
transient and more widespread, often consisting of smal-
ler or larger elevated wheals. The exact pathomechanism 
of EM is unclear, although it has been suggested that it 
is bradykinin-mediated (10, 11). Traditional anti-allergic 
treatment regimens have proven ineffective in HAE-
related EM and angioedema.
It has long been a clinical dogma, that patients with 
HAE do not have urticaria, which might cause some 
clinicians to pre-exclude this important diagnosis when 
urticarial rash and angioedema occur together or the 
patient reports urticaria in the disease history (11–14). 
Misdiagnosis of EM as urticaria might therefore con-
tribute to diagnostic confusion and significant delay in 
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Fig. 1. Erythema marginatum. Erythema marginatum in two separate 
patients: back of a woman (top) and thorax of a young man (bottom).
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the diagnosis of HAE, leading to ineffective and poten-
tially harmful treatment regimens with anti-histamines, 
glucocorticoids and/or adrenaline.
In this study we report the incidence of urticaria and 
prodromal symptoms, including EM, in a cohort of 
Danish HAE patients with a focus on diagnostic chal-
lenges of skin signs. 
MATERIALS AND METHODS
Inclusion criteria were HAE type I or II and attendance at the 
national HAE Centre in Denmark. Eighty-eight HAE patients 
were included, but one patient had died at the time of follow-up 
and was excluded due to a lack of information, leaving 87 pa-
tients for data analysis. Adult patients provided written consent 
prior to participation in this study and parents provided written 
consent on behalf of their children. Although some patients had 
their initial HAE testing carried out at other health facilities, 
all patients had the diagnosis confirmed at the HAE Centre.
The study comprised 3 separate parts: (i) baseline data col-
lection: at the first visit in the HAE Centre, patients completed 
purposely designed questionnaires with questions about skin 
eruptions, prodromal symptoms, treatment regimens and their ef-
fectiveness. The patients were assisted by a trained dermatologist 
in the process of completing the questionnaires. Special emphasis 
was put on the difference between EM and urticarial eruptions. 
Family history was explored and pedigrees were drawn in order 
to identify other possible HAE patients and assess the likelihood 
of hereditability or de novo mutation. Medical records from other 
hospitals were retrieved and reviewed when deemed relevant. (ii) 
Prospective data collection: once the patient was enrolled at the 
HAE Centre medical records were kept updated regarding symp-
toms, prodromes, treatment regimens, effectiveness, well-being 
and other relevant medical and social information. Furthermore, 
patients completed a HAE-specific diary, which was also used 
as an evaluation tool at each visit. (iii) Follow-up: in patients 
with a lack of information in their diaries (especially children), 
an e-mail was sent or a telephone call made at the end of 2013 
or beginning of 2014 to retrieve updated information. 
Microsoft Excel for Windows 8 and STATA version 13 were 
used for data analysis.
This study was approved by the Danish Data Protection 
Agency (number 2009-41-2987). In Denmark questionnaire 
studies are not required to be approved by an ethics commit-
tee. The study was conducted according to the principles of the 
Declaration of Helsinki.
RESULTS
Eighty-seven patients were identified, with a male:female 
ratio of 1.02 (Table I). Four children were still asymp-
tomatic. Sixty-four patients (74%) could always or so-
metimes predict an upcoming attack, which meant that 
they had some kinds of prodromal symptoms. Forty-nine 
patients (56%) had experienced EM. A total of 22 patients 
(25%) reported former episodes of urticaria (cold urtica-
ria, symptomatic dermographism combined with delayed 
pressure urticaria and chronic spontaneous urticaria) or 
events with urticarial lesions, which in 3 cases could be 
related to penicillin allergy or infusion of fresh frozen 
plasma (Table II). A total of 13 patients (27%) reported 
former episodes of EM as well as urticarial lesions. Half 
of all patients experiencing EM reported that EM has 
been misinterpreted as being urticaria by healthcare per-
sonnel primarily at the emergency department or by their 
general practitioner. In support of this finding, the mean 
diagnostic delay was almost 2 years longer in patients 
with EM. A high percentage of patients had been treated 
with anti-allergic medications before they were correctly 
diagnosed with HAE and these medications had little or 
no effect on EM or angioedema. However, patients who 
had both urticarial lesions and EM were, in most cases, 
not able to distinguish between the efficacy of anti-allergic 
treatment on their urticaria vs. EM, as, in the past, many 
were not aware of the differences between the 2 entities. 
Seventy-eight patients answered additional questions 
concerning prodromal symptoms (Table III). The most 
Table I. Characterization of the Danish cohort of 87 patients with 
hereditary angioedema (HAE) 
Characteristics
Patients, male/female, n 44/43
Male:female ratio 1.02
Age, years, median, (range) 41 (0–83)
HAE type Ia, n (%) 81 (93)
HAE type IIb, n (%) 6 (7)
Children <18 years old, n 17
Adults, n 70
Diagnostic delay, in patients without EM, years, mean 15.6
Diagnostic delay in patients with EM, years, mean 17.7
Can predict an oncoming attack, patients, n (%) 
  Always before an attack
  Sometimes 
  Never 
  Patient unsure 
  No verified attacks 
  Missing data
37 (43)
27 (31)
12 (14)
2 (2)
4 (5)
5 (6)
a 81 individuals from 29 families; b 6 individuals from 2 families.
EM: erythema marginatum.
Table II. Urticarial eruptions and erythema marginatum (EM) 
in 83 symptomatic patients with hereditary angioedema 
History of EM, n (%)
  Yes 
  No 
  Patient unsure 
49 (56)
37 (43)
  1 (1)
Lifetime prevalence of urticarial eruptions, n (%)
  Yes 
  Penicillin allergy 
  Cold urticaria
  Combined delayed pressure urticaria and dermatographism
  Provoked by fresh frozen plasma infusion
  Chronic spontaneous urticaria
  Unspecified
  No 
  No data 
22 (25)
  2 
  1 
  1 
  1 
  1
16 
63 (72)
  2 (2)
History of EM and urticarial eruptions, n (%)a 13 (27)
History of EM misinterpreted as urticaria, n (%)
  Yes 
  No
  Patient unsure 
  No data
25 (29)
60 (69)
  1 (1)
  1 (1)
aPatients with erythema marginatum (EM). Numbers are rounded and there-
fore do not always add up to 100%.
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frequent prodrome was EM, followed by tightness or 
a prickling sensation of the skin, pruritus, malaise, 
psychological changes, such as irritability and anxiety, 
fatigue and gastrointestinal complaints (nausea, vomit-
ing, abdominal pain, diarrhoea, hunger, thirst, distended 
abdomen and abdominal discomfort). Only one patient 
below the age of 12 years could consistently report a 
prodromal symptom (headache).
DISCUSSION 
To our knowledge, no previous studies have been car-
ried out systematically to assess the lifetime prevalence 
of skin eruptions in a large cohort of HAE patients. In 
this cohort the incidence proportion (or cumulative 
incidence) of EM and urticaria or urticarial lesions were 
56% and 25%, respectively. More than 1/4 experienced 
both features. Half of our patients with EM had their 
rash misinterpreted as urticaria at least once. Magerl et 
al. (14) recently demonstrated a statistically significant 
longer diagnostic delay in HAE patients experiencing 
EM. The diagnostic delay in our study was 2 years 
longer in patients with EM. 
In a prospective study by Prematta et al. (15) the 
prevalence of hives as prodromal symptom varied from 
4% to 25% depending on anatomical region. Patients 
might have used the term “hives” instead of EM, al-
though investigators asked patients about “non-itchy 
rash with pale centres” suggestive of EM. In our study, 
the questionnaire was completed with the support of 
a dermatologist, emphasizing the differences between 
urticaria and EM. Also, patients with any “rash” had a 
clear sense of the differences in clinical presentation, e.g. 
itching or non-itching. Data is not directly compar able 
however, as we report “per-patient” rather than “per-at-
tack” data. In a retrospective questionnaire-based survey 
of 46 patients with HAE, Prematta et al. (5) reported that 
33% of patients described a rash on the trunk and 48% 
reported a rash on arms or legs before their most recent 
angioedema attack. Although no details regarding this 
sign were stated, one could presume that most patients 
described EM. A retrospective survey reported a lifetime 
prevalence of 42% regarding prodromal “rash” in 33 
patients with HAE, but no further definition of the rash 
was made (6). Nielsen et al. (16) described “iris-like red 
and slightly elevated circles in the skin before or during 
attacks”, presumably EM, in 50% of patients with HAE. 
Furthermore, they reported one child being hospitalized 
because of presumed urticaria. In our cohort a young boy 
was likewise hospitalized several times with angioedema 
and “viral rash”, “erythema multiforme” and “allergy” 
(17). In this particular patient EM was observed for the 
first time when he was only a few weeks old and several 
years before he had his first swelling attack. This example 
highlights the need for C1INH testing when a diagnostic 
“clue”, like EM, presents in patients without angioedema. 
The main challenge when carrying out retrospective 
studies is recall bias. However, since 2001 we col-
lected prospective data using patient diaries, which 
were upgraded to an extended version in 2013 made 
electronically in 2014. 
The exact pathomechanism of EM is unknown. A 
single study demonstrated a localized accumulation of 
bradykinin in the stromal tissue and endothelial cells 
in a skin biopsy (11). This observation is supported 
by the clinical experience that traditional anti-allergic 
treatment regimens are not effective in EM or HAE in 
general. This subject needs further assessment. 
One patient had symptomatic dermographism and 
delayed pressure urticaria, one patient had cold urti-
caria, 2 patients reported urticarial eruptions during 
penicillin treatment and one patient had chronic spon-
taneous urticaria. These numbers are comparable with 
the known incidences in the background population 
(18–20). Lifetime prevalence of urticaria in the general 
population has been stated to be approximately 20% 
(21). No data exist in the literature on urticaria incidence 
or prevalence in HAE populations, but in this study the 
lifetime prevalence of urticaria or urticarial lesions due 
to other medical conditions was (i.e. penicillin allergy, 
cold urticaria, pressure urticaria) 25%. 
However, bradykinin-mediated angioedema should not 
be ruled out solely on the presence of a positive medical 
history for urticarial lesions (22). Recently interesting 
studies on murine C1INH knock-out models have revea-
led a possible role of subclinical mast cell activation in 
the initiation of attacks in patients with HAE. This could 
potentially predispose for urticarial eruptions and vice 
versa urticaria might activate angioedema in patients with 
HAE; however, further investigation is required (23, 24).
Increasing attention is being paid to prodromal symp-
toms of HAE, as the ability to foresee an oncoming attack 
is paramount in timely on-demand treatment. Regimens 
of home therapy enable the patient to treat attacks at 
an early stage to avoid progression of the oedema. Our 
study thus included data on prodromal symptoms other 
Table III. Patients reporting prodromal symptoms including 
erythema marginatum (n = 71); 53 patients experienced more 
than one prodromal symptom (why % does not add up to 100%)
Symptoms n (%)
Skin
  Erythema marginatum
  Pressure, prickling sensation, tightness 
  Pruritus
  Other, i.e. changed sensitivity
49 (56)
32 (37)
12 (14)
  6 (7)
Malaise 23 (26)
Psychological changes (irritability and anxiety) 19 (22)
Fatigue 18 (21)
Gastrointestinal symptoms 14 (16)
Excessive perspiration or unpleasant body odour 5 (6)
Change in temperature perception 3 (3)
Dysuria (including ”foul-smelling urine”) 3 (3)
Headache 2 (2)
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than skin manifestations and showed that more than 
90% of symptomatic patients with HAE experienced 
prodromal symptoms. In concordance with several other 
prospective and retrospective studies, we found a high 
prevalence of malaise (27%) and fatigue (21%) (5, 6, 
25). Skin symptoms other than rash were also significant 
findings in our cohort (38%). In one prospective study 
the per-attack incidence of skin-related symptoms was 
significantly lower (15). Psychological changes have con-
sistently been reported as prodromal features by patients 
with HAE, with a prevalence ranging from 15% in the 
literature to 21% in this study (6, 26). Symptoms related 
to the digestive tract were frequent in our study (17%) 
as in other reports (12–61%); prodromes related to the 
gastrointestinal system were especially found to precede 
abdominal attacks (5, 6, 15). This is predictable, since 
>50% of HAE attacks are located to the intestinal mucosa 
and an attack can be initializing for several hours causing 
abdominal discomfort. We suggest that these prodromes 
may, in fact, be signs of early swellings. In other studies 
joint and muscle pain were often reported, but that was not 
the case in our patient group (5, 6). This might, however, 
be due to lack of attention to these symptoms. 
In conclusion, these results show that 50% of patients 
with HAE experiencing EM have the rash misdiagnosed 
as urticaria, even by medical personnel. This leads to 
inefficient treatment regimens with anti-allergic medi-
cations and may delay diagnosis of HAE. Also, more 
than 90% of patients with HAE experience prodromal 
symptoms; which may help patients and physicians to 
decide when to treat an oncoming attack. Further stu-
dies, preferably with a prospective design, are needed 
to elucidate these facts. 
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